Home
/
Data resources
/
Literature
/
31773340
Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.

Gastric Cancer, 2020/05;23(3):473-482.

Kim SK[1], Kim HJ[2], Park JL[2], Heo H[1, 3], Kim SY[1, 3], Lee SI[4], Song KS[5], Kim WH[6], Kim YS[7, 8]

Affiliations

PMID: 31773340DOI: 10.1007/s10120-019-01029-4

Impact factor: 7.701

Abstract
background: Although recent advances in high-throughput technology have provided many insights into gastric cancer (GC), few reliable biomarkers for diffuse-type GC have been identified. Here, we aim to identify a prognostic and predictive signature of diffuse-type GC heterogeneity.
methods: We analyzed RNA-seq-based transcriptome data to identify a molecular signature in 150 gastric tissue samples including 107 diffuse-type GCs. The predictive value of the signature was verified using other diffuse-type GC samples in three independent cohorts (n = 466). Log-rank and Cox regression analyses were used to estimate the association between the signature and prognosis. The signature was also characterized by somatic variant analyses and tissue microarray analysis between diffuse-type GC subtypes.
results: Transcriptomic profiling of RNA-seq data identified a signature which revealed distinct subtypes of diffuse-type GC: the intestinal-like (INT) and core diffuse-type (COD) subtypes. The signature showed high predictability and independent clinical utility in diffuse-type GC prognosis in other patient cohorts (HR 2.058, 95% CI 1.53-2.77, P = 1.76 × 10-6). Integrative mutational and gene expression analyses demonstrated that the COD subtype was responsive to chemotherapy, whereas the INT subtype was responsive to immunotherapy with an immune checkpoint inhibitor (ICI). Tissue microarray analysis showed the practical utility of IGF1 and NXPE2 for predicting diffuse-type GC heterogeneity.
conclusions: We present a molecular signature that can identify diffuse-type GC patients who display different clinical behaviors as well as responses to chemotherapy or ICI treatment.

Keywords: Chemotherapy; Diffuse-type GC; Gastric cancer; Immune checkpoint inhibitor; Prognosis

MeSH terms
Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Intercellular Signaling Peptides and Proteins; Intestinal Neoplasms; Male; Middle Aged; Prognosis; Stomach Neoplasms; Survival Rate; Transcriptome; Tumor Cells, Cultured
More resources
EndNote: Download